Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Common Equity (2021 - 2025)

Rxo (RXO) has disclosed Common Equity for 5 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 4.4% year-over-year to $1.5 billion, compared with a TTM value of $1.5 billion through Dec 2025, down 4.4%, and an annual FY2025 reading of $1.5 billion, down 4.4% over the prior year.
  • Common Equity was $1.5 billion for Q4 2025 at Rxo, down from $1.6 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.7 billion in Q3 2024 and bottomed at $579.0 million in Q2 2024.
  • Average Common Equity over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2021.
  • The sharpest move saw Common Equity crashed 50.88% in 2023, then soared 180.0% in 2024.
  • Year by year, Common Equity stood at $1.1 billion in 2021, then plummeted by 45.14% to $587.0 million in 2022, then increased by 1.19% to $594.0 million in 2023, then skyrocketed by 171.38% to $1.6 billion in 2024, then decreased by 4.4% to $1.5 billion in 2025.
  • Business Quant data shows Common Equity for RXO at $1.5 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.6 billion in Q2 2025.